Lisa Wohl, MD
Ophthalmology · Bloomingdale, ILNPI 1598701625
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $13,050 of the $20,606 with a category attached, or 63.3%. 18 manufacturers reported payments, led by Shire North American Group Inc at 41.3% of the total. Reporting peaked in 2019 at $14,973 and has fallen 93.7% since, to $949 in 2025. Among ophthalmology clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 148 payments — averaging $139.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shire North American Group Inc$9K
- Novartis$4K
- AbbVie$3K
- Dompe US, Inc.$2K
- Alcon$2K
- Bausch & Lomb Americas Inc.$429
- plus $1K from 12 others
Across 1 payment — averaging $429.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Shire North American Group Inc$430
What the payments were for
- Consulting fees$2,01310%
- Speaking & faculty fees$13,05063%
- Travel & lodging$1,0325%
- Food & beverage$4,49522%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shire North American Group Inc | 20 | $8,509 |
| Novartis | 17 | $3,896 |
| AbbVie(2 entities) | 29 | $2,972 |
| Dompe US, Inc. | 5 | $2,098 |
| Alcon | 24 | $1,521 |
| Bausch & Lomb Americas Inc. | 13 | $429 |
| Sun Pharmaceutical Industries Inc. | 9 | $230 |
| Aerie Pharmaceuticals, Inc. | 6 | $202 |
| Glaukos Corporation | 2 | $161 |
| Oyster Point Pharma, Inc. | 7 | $146 |
| Thea Pharma Inc. | 5 | $117 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $109 |
| Harrow Eye, LLC | 3 | $92 |
| Tarsus Pharmaceuticals, Inc. | 2 | $57 |
| Sight Sciences, Inc. | 1 | $21 |
| Kala Pharmaceuticals, Inc. | 1 | $21 |
| NEW World Medical,inc. | 1 | $18 |
| Notal Vision, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIIDRA$11,841
- RESTASIS$2,510
- Oxervate$2,013
- ARGOS$253
- NGENUITY$249
- Hydrus Microstent$149
- TRYPTYR$122
- iStent Trabecular Micro-Bypass Stent System$117
- iStent inject Trabecular Micro-Bypass Stent System$117
- Rocklatan$110
- Rhopressa$110
- AcrySof IQ PanOptix UV IOL$102
- AcrySof IQ VIVITY$102
How this compares
$20,606 in reported general payments places this provider in the 90th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 304 | $251,314 |
| XiidraLifitegrast | 117 | $107,513 |
| MieboPerfluorohexyloctane/Pf | 58 | $53,248 |
| LumiganBimatoprost | 75 | $44,801 |
| VevyeCyclosporine | 29 | $27,220 |
| Cyclosporine | 83 | $20,482 |
| Prednisolone Acetate | 692 | $19,329 |
| Ofloxacin | 491 | $4,892 |
| Latanoprost | 402 | $4,207 |
| Travoprost | 20 | $2,286 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 11 | $2,232 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 137 | $2,139 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 35 | $1,189 |
| Brimonidine Tartrate | 116 | $1,164 |
| Ketorolac Tromethamine | 63 | $1,100 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $2,972 | $296,114379 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $429 | $160,762175 claims |
| Harrow Eye, LLCVevye | $92 | $27,22029 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 773 ophthalmology providers in Illinois.
Other ophthalmology in Bloomingdale
- Seenu HariprasadChicago$2.3M
- Lisa NijmSpringfield$1.7M
- Kathleen MornoNorth Riverside$1.2M
- Veeral ShethOak Forest$716K
- James KatzDes Plaines$642K
- Mitchell JacksonLake Villa$584K
- David LubeckHomewood$575K
- Parag MajmudarHighland Park$451K
- Daniel OwensLombard$343K
- Yannek LeidermanChicago$312K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.